Avid Bioservices, Inc.
CDMO
$8.25
$0.050.61%
| Weiss Ratings | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | C- | |||
| Rating Factors | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.20 | |||
| Price History | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 13.71% | |||
| 30-Day Total Return | 25.29% | |||
| 60-Day Total Return | 12.70% | |||
| 90-Day Total Return | 24.67% | |||
| Year to Date Total Return | 19.97% | |||
| 1-Year Total Return | -57.61% | |||
| 2-Year Total Return | -49.47% | |||
| 3-Year Total Return | -63.68% | |||
| 5-Year Total Return | 57.97% | |||
| 52-Week High % Change | -61.19% | |||
| 52-Week Low % Change | 79.83% | |||
| Price | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $19.97 | |||
| 52-Week Low Price | $4.07 | |||
| 52-Week Low Price (Date) | Dec 08, 2023 | |||
| 52-Week High Price (Date) | Apr 24, 2023 | |||
| Valuation | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 404.10M | |||
| Enterprise Value | 569.37M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.18 | |||
| Earnings Per Share Growth | -116.92% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.86 | |||
| Price/Book (Q) | 2.20 | |||
| Enterprise Value/Revenue (TTM) | 4.61 | |||
| Price | $7.63 | |||
| Enterprise Value/EBITDA (TTM) | -99.76 | |||
| Enterprise Value/EBIT | -38.31 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 63.32M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 714-508-6100 | |||
| Address | 14191 Myford Road Tustin, CA 92780 | |||
| Website | www.avidbio.com | |||
| Country | United States | |||
| Year Founded | 1981 | |||
| Profitability | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -12.03% | |||
| Profit Margin | -13.10% | |||
| Management Effectiveness | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -2.27% | |||
| Return on Equity | -- | |||
| Income Statement | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 136.74M | |||
| Total Revenue (TTM) | 136.74M | |||
| Revenue Per Share | $2.16 | |||
| Gross Profit (TTM) | 14.87M | |||
| EBITDA (TTM) | -6.32M | |||
| EBIT (TTM) | -16.45M | |||
| Net Income (TTM) | -17.92M | |||
| Net Income Avl. to Common (TTM) | -17.92M | |||
| Total Revenue Growth (Q YOY) | -11.06% | |||
| Earnings Growth (Q YOY) | -- | |||
| EPS Diluted (TTM) | -0.28 | |||
| EPS Diluted Growth (Q YOY) | -1,382.43% | |||
| Balance Sheet | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 30.71M | |||
| Cash Per Share (Q) | $0.48 | |||
| Total Current Assets (Q) | 103.59M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 180.17M | |||
| Current Ratio (Q) | 0.465 | |||
| Book Value Per Share (Q) | $2.84 | |||
| Total Assets (Q) | 455.23M | |||
| Total Current Liabilities (Q) | 222.89M | |||
| Total Debt (Q) | 194.90M | |||
| Total Liabilities (Q) | 275.06M | |||
| Total Common Equity (Q) | 180.17M | |||
| Cash Flow | CDMO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -50.99M | |||
| Cash from Financing (TTM) | 8.94M | |||
| Net Change in Cash (TTM) | -29.56M | |||
| Levered Free Cash Flow (TTM) | -51.04M | |||
| Cash from Operations (TTM) | 12.49M | |||
